AB0736 Secukinumab Significantly Improves Physical Function, Quality of Life, and Work Productivity Through 52 Weeks in Subjects with Active Ankylosing Spondylitis in the Phase 3 Measure 2 Study

Abstract

BackgroundInterleukin (IL)-17A is implicated in the pathogenesis of ankylosing spondylitis (AS),1 and inhibition of this cytokine with secukinumab, a human anti–IL-17A monoclonal antibody, has previously demonstrated rapid reduction in the...